Skip to main content

Table 1 Summary of input parameters into health economic model

From: A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females

Input parameters

Base Case Value

References

Vaccination

  

Efficacy HPV 16/18

98% (95% CI: 88.4-1000)

[8–11]

Efficacy non-vaccine oncogenic HPV types

37% (95% CI: 7.4-58.0)

[8, 9]

Duration of vaccine protection

lifelong

Assumption

Coverage rate

75%

Assumption based on [50]

Screening

  

Age and frequency

Age 18-69, 70% (once/3 years), 12% (never)

[39]

Cytology (Pap) test sensitivity

55.4%

[57]

Cytology (Pap) test specificity

96.8%

[57]

Costs and utilities

  

Vaccination costs

  

Vaccine per dose

$135.00

Assumption

Screening Costs

  

Conventional cytology

$57

[7, 48]

Colposcopy + Biopsy

$150

[7, 48]

Treatment Costs (annual)

  

CIN 1

$782

[7, 48]

CIN 2/3

$1,353

[7, 48]

Cervical cancer stage 1

$11,915

[7, 48]

Cervical cancer stage 2

$18,851

[7, 48]

Cervical cancer stage 3

$18,851

[7, 48]

Cervical cancer stage 4

$25,759

[7, 48]

Utilities

  

Normal Population

0.94-0.89 (age-specific)

[58]

CIN lesion

0.96-0.995

[59, 60]

Cervical cancer

0.73

[59, 60]

Cured cancer

0.94

[61]